scholarly article | Q13442814 |
P819 | ADS bibcode | 2015PLoSO..1043643H |
P356 | DOI | 10.1371/JOURNAL.PONE.0143643 |
P932 | PMC publication ID | 4669153 |
P698 | PubMed publication ID | 26633806 |
P5875 | ResearchGate publication ID | 285594973 |
P50 | author | Hirokazu Tanino | Q70967073 |
P2093 | author name string | Takashi Ishikawa | |
Yoshie Hasegawa | |||
Norio Kohno | |||
Daishu Miura | |||
Jun Horiguchi | |||
Kazuhiko Yamagami | |||
Kouhei Akazawa | |||
Masaru Miyashita | |||
Masato Suzuki | |||
Mitsuhiro Hayashi | |||
Muneharu Konishi | |||
Seung Jin Kim | |||
Shintaro Takao | |||
Tetsuya Taguchi | |||
Tomoyuki Kubota | |||
Yasushi Shigeoka | |||
P2860 | cites work | Safety of zoledronic acid and incidence of osteonecrosis of the jaw (ONJ) during adjuvant therapy in a randomised phase III trial (AZURE: BIG 01-04) for women with stage II/III breast cancer. | Q53434420 |
Addition of zoledronic acid to neoadjuvant chemotherapy does not enhance tumor response in patients with HER2-negative stage II/III breast cancer: the NEOZOTAC trial (BOOG 2010-01). | Q54373964 | ||
Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO-FAST study): final 60-month results | Q87419544 | ||
Development of bisphosphonates | Q21195188 | ||
The effects of adding zoledronic acid to neoadjuvant chemotherapy on tumour response: exploratory evidence for direct anti-tumour activity in breast cancer | Q24597847 | ||
Effect of zoledronic acid on disseminated tumour cells in women with locally advanced breast cancer: an open label, randomised, phase 2 trial | Q30416847 | ||
Combined effects of the bisphosphonate, zoledronic acid and the aromatase inhibitor letrozole on breast cancer cells in vitro: evidence of synergistic interaction | Q33531646 | ||
Zoledronic acid directly suppresses cell proliferation and induces apoptosis in highly tumorigenic prostate and breast cancers | Q34025648 | ||
Antitumor activity of zoledronic acid in primary breast cancer cells determined by the ATP tumor chemosensitivity assay | Q34348233 | ||
Endocrine therapy plus zoledronic acid in premenopausal breast cancer. | Q34943802 | ||
The backbone of progress--preclinical studies and innovations with zoledronic acid | Q37847339 | ||
Sustained inhibition of tumor growth and prolonged survival following sequential administration of doxorubicin and zoledronic acid in a breast cancer model. | Q39822665 | ||
Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial. | Q42603658 | ||
Breast-cancer adjuvant therapy with zoledronic acid | Q42620139 | ||
Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trial | Q43911264 | ||
P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
P6216 | copyright status | copyrighted | Q50423863 |
P433 | issue | 12 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | zoledronic acid | Q218507 |
chemotherapy | Q974135 | ||
P304 | page(s) | e0143643 | |
P577 | publication date | 2015-01-01 | |
P1433 | published in | PLOS One | Q564954 |
P1476 | title | Randomized Controlled Trial of Zoledronic Acid plus Chemotherapy versus Chemotherapy Alone as Neoadjuvant Treatment of HER2-Negative Primary Breast Cancer (JONIE Study) | |
P478 | volume | 10 |
Q92910688 | Addition of zoledronic acid to neoadjuvant chemotherapy is not beneficial in patients with HER2-negative stage II/III breast cancer: 5-year survival analysis of the NEOZOTAC trial (BOOG 2010-01) |
Q47693752 | Bisphosphonates and other bone agents for breast cancer. |
Q92848745 | Efficacy and safety of neoadjuvant chemotherapy regimens for triple-negative breast cancer: a network meta-analysis |
Q88573696 | Inhibition of UGT8 suppresses basal-like breast cancer progression by attenuating sulfatide-αVβ5 axis |
Q39375196 | Neoadjuvant Therapy for Breast Cancer: Established Concepts and Emerging Strategies. |
Q98164813 | Repurposing of drugs for triple negative breast cancer: an overview |
Q38733725 | The Effect of Everolimus in an In Vitro Model of Triple Negative Breast Cancer and Osteoclasts. |
Search more.